Lars Van Der Veen
Company: iOnctura
Job title: Chief Scientific Officer
Seminars:
Shedding Light on a Novel PI3K Inhibitor: Enabling Isoform-Specific Inhibition to Establish Clinical Success 9:00 am
Examining the mode of action of a novel, non-ATP competitive PI3Kd inhibitor and its pharmacological activity Dissecting isoform-dependent toxicity profiles for an improved assessment of therapeutic index Highlighting the importance of a selectivity-matched PK profile to optimize the therapeutic potential for clinical developmentRead more
day: Conference Day Two